The National Institute on Aging (NIA) awarded a $3,579,235 Project Grant under the Aging Research Federal Grant Program (CFDA 93.866) to the University of Massachusetts Medical School (UMass Medical) to study the role of peripheral insulin resistance and inflammation in Alzheimer's disease (AD) pathogenesis. The key objectives are to: 1) Define age-related changes in metabolism and inflammation in peripheral organs and the brain during AD-relevant neurodegeneration in a mouse model, and 2)...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $218,261 to the University of Virginia to conduct research on the molecular connection between obesity and Alzheimer's disease (AD). The principal investigator aims to: 1) genetically identify the pathways through which obesity activates the protein MOAG-4/SERF2 in neuronal cells, and 2) determine how MOAG-4/SERF2 mediates the neurological and motor decline observed in obesity-induced animal...
The National Institute on Aging (NIA) awarded a $372,400 Project Grant under the Aging Research program (CFDA 93.866) to Nova Southeastern University to evaluate the therapeutic potential of three novel compounds - tirzepatide, retatrutide, and crocetin - in mitigating Alzheimer's-like pathology in a mouse model with comorbid obesity and prediabetes. The research aims to assess the impact of these interventions on cognitive-behavioral function, neuropathological changes, and cardiometabolic...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research on the impact of brain lipoprotein structure and composition on amyloid beta metabolism and Alzheimer's disease. The $2,335,492 award to Battelle Memorial Institute's Pacific Northwest National Laboratory will fund a 5-year study to assess how differences in apolipoprotein E (APOE) isoforms affect brain lipoprotein distribution, composition, and ability to bind amyloid beta. The...
The National Institute on Aging (NIA) awarded a $125,896 Project Grant under the Aging Research program (CFDA 93.866) to The Washington University in St. Louis to conduct research on Alzheimer's disease (AD) risk and resilience pathways. The project aims to perform deep molecular characterization of AD genetic risk factors and protective mechanisms using state-of-the-art single-cell multi-omic analyses of healthy and AD human brain tissue, as well as transgenic AD mouse models. Key objectives...
The National Institute on Aging (NIA) awarded a $2,330,235 Project Grant (CFDA 93.866 - Aging Research) to Rush University Medical Center in Chicago, IL to examine the relationship between diet, neuroinflammation, brain oxidative stress, and plasma neurodegenerative biomarkers. The 5-year project, beginning in Sep 2024, aims to elucidate the link between diet and Alzheimer's disease/age-related dementias (AD/ADRD) by leveraging data from four longitudinal community cohorts. Key objectives...
The National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), awarded a $1,684,689 project grant to Weill Medical College of Cornell University to study the role of microglial lysosomes in the degradation of amyloid-beta, a key pathological feature of Alzheimer's disease. The 3-year project aims to characterize the process of "digestive exophagy" used by microglia to limit the expansion of amyloid-beta plaques, as well as explore the effects of genetic...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) for $2,273,637 aims to conduct a comprehensive lipidomics study to investigate the relationship between plasma and brain lipid profiles, cognitive decline, and the onset of Alzheimer's disease (AD) and other dementias. The study will leverage the Cardiovascular Health Study cohort to examine the association of plasma lipidomic species with risks of incident AD, total dementia, and cognitive decline. It...
This National Institute on Aging (NIA) Project Grant award under the Aging Research federal grant program (CFDA 93.866) provides $372,690 to the University of California, Berkeley to uncover the heterogeneous causal pathophysiology of Alzheimer's disease (AD). The project aims to develop novel statistical methods to analyze existing datasets and reveal optimal treatment windows and target populations for whom reducing amyloid-beta or tau levels is most likely to yield cognitive benefits. Key...
This $342,934.65 project grant from the Department of Health and Human Services National Institutes of Health National Institute on Aging, under the Aging Research program (CFDA 93.866), will fund research into acyl chain remodeling and regional lipid dysregulation in Alzheimer's disease. The Trustees of Columbia University in the City of New York, doing business as Health Sciences Division, will analyze lipid composition in brain regions susceptible to Alzheimer's disease, such as the...
This National Institute on Aging (NIA) Project Grant, awarded under the Aging Research program (CFDA 93.866), aims to investigate how obesity-induced changes in the liver impact the development of Alzheimer's disease (AD) pathology. The $405,849 award to Keck Graduate Institute of Applied Life Sciences will support a 2-year study with the following objectives:
Examine the relationship between obesity-induced dysregulation of amyloid-beta (Aβ) processing in the liver and increased Aβ levels in the brain, and how this impacts AD pathology in mouse models.
Determine the specific contributions of hepatic amyloid precursor protein (APP) overexpression and lipoprotein receptor-related protein 1 (LRP1) silencing, hallmarks of fatty liver disease, in driving peripheral and brain Aβ levels and AD pathology.
This integrated research aims to provide new insights into the liver-brain axis in obesity-related AD, potentially identifying novel therapeutic targets for this debilitating neurodegenerative condition.